AEGEA’s patented and validated Switch-Blocker technology platform dramatically improves the analytical sensitivity and specificity for detecting and quantifying rare gene events, such as mutations, Single Nucleotide Polymorphisms (SNPs) and other disease biomarkers. Single nucleotide specificity and single copy sensitivity are achievable because Switch-Blockers suppress wild type while amplifying mutant.